KIT A502_Y503 duplication mutation serves as a potential and universal target for neoantigen peptide in Chinese GIST patients
Journal of Gastroenterology and Hepatology · 2023
DOI: 10.1111/jgh.16165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2023. Verfasst von Fangcen Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Gastrointestinal Stromal Tumors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Natural Science Foundation of China, Primary Research and Development Plan of Jiangsu Province, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Background and Aim Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor with high prevalence of KIT and PDGFRA mutations. Few effective treatments can be exploited in imatinib or sunitinib resistant cases. While in immunotherapy, application of the highly individualized cancer neoantigen vaccines is hampered due to high economic and time cost. In this study we identified the most frequent mutation in Chinese GIST patients and predicted candidate neopeptide by next generation sequencing (NGS).
Methods
Tumor tissues and matched blood samples of 116 Chinese GIST patients were collected. Genomic profile was detected through NGS, and 450 cancer genes were deeply sequenced. KIT mutations were identified, and long peptides containing the mutation were queried in NetMHCpan 4.0 tools to predict MHC class I binding of mutant peptides.
Results
The most frequent mutated genes in detected GIST patients were KIT (81.9%, 95/116), CDKN2A (18.97%, 22/116), and CDKN2B (15.52%, 18/116) in this cohort. The most common mutation of KIT was A502_Y503 duplication (15.93%, 18/113) in exon 9. Among the 116 cases, 103 were HLA I genotyped, and 101 were HLA II genotyped. In total, 16 samples with the mutation of KIT p.A502_Y503dup were identified to produce neoantigens with qualified HLA affinity.
Conclusions
KIT hotspot mutation (p.A502_Y503dup) has the highest incidence, which may further eliminate the need for whole genome sequencing and patient‐specific neoantigen prediction and synthesis. Therefore, for those carrying such mutation, accounting for around 16% of Chinese GIST patients and are usually less sensitive to imatinib, effective immunotherapies are in prospect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
- The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School and Clinical Cancer Institute of Nanjing University, Nanjing, China.
- Shanghai OrigiMed Co., Ltd, Shanghai, China.
ORCID-Profile: Rutian Li
Förderung
- Natural Science Foundation of China
- Primary Research and Development Plan of Jiangsu Province
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
- Jiangsu Provincial Key Research and Development Program
Zitieren
APA
Liu, F., Wang, Q., Li, Y., Li, L., Shi, J., Fan, X., Pan, Q., & Li, R. (2023). KIT A502_Y503 duplication mutation serves as a potential and universal target for neoantigen peptide in Chinese GIST patients. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16165
Vancouver
Liu F, Wang Q, Li Y, Li L, Shi J, Fan X, et al. KIT A502_Y503 duplication mutation serves as a potential and universal target for neoantigen peptide in Chinese GIST patients. Journal of Gastroenterology and Hepatology. 2023. doi:10.1111/jgh.16165
BibTeX
@article{Liu2023,
author = {Liu, Fangcen and Wang, Qin and Li, Yishan and Li, Lin and Shi, Jiaochun and Fan, Xiangshan and Pan, Qiuyue and Li, Rutian},
title = {KIT A502_Y503 duplication mutation serves as a potential and universal target for neoantigen peptide in Chinese GIST patients},
journal = {Journal of Gastroenterology and Hepatology},
year = {2023},
doi = {10.1111/jgh.16165}
}
EUVIMED